VivoSeq
Psychiatry

Cocaine Use Disorder

26

Pipeline Programs↗

9

Active Trials↗

15

Companies Involved↗

Cocaine Use Disorder is an emerging landscape with 26 programs across 15 companies. The most active players are Omnivium, COMPASS Pathways, AstraZeneca. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

71/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Omnivium

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1N

Noven Pharmaceuticals, Inc.

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2E

Embera NeuroTherapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

24 of 27 classified programs — the dominant modality here.

11%ALL OTHERSPeptide27%Gene therapy14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.

Analysis

Trial Status

24

clinical trials

Completed10 · 42%
Recruiting7 · 29%
Terminated2 · 8%
Active, not recruiting1 · 4%
Unknown status1 · 4%
Suspended1 · 4%
Other2 · 8%

Clinical Trials

Trial Activity

24 trials

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Recruiting·VVirginia Commonwealth University·Phase 2·NCT05886582·40 enrolled
Safety Profile of Psilocybin for Cocaine Use Disorder
Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT06102434·10 enrolled
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06691243·40 enrolled
AAV8-hCocH for Cocaine Use Disorder
Recruiting·—·Phase 1·NCT04884594·10 enrolled
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT07227948·75 enrolled
Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)
Recruiting·—·Phase 1·NCT05008146·80 enrolled
[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)
Recruiting·—·Phase 1·NCT05011760·30 enrolled
Clavulanic Acid for the Treatment of Cocaine Use Disorder
Active, not recruiting·TTemple University·Phase 2·NCT05562349·65 enrolled
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
Not yet recruiting·PParnassia Addiction Research Centre·Phase 2·NCT05529927·204 enrolled
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
Completed·EEmbera NeuroTherapeutics, Inc.·Phase 2·NCT04501874·82 enrolled
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
Completed·Novartis logoNovartis·Phase 2·NCT03242928·68 enrolled
[11C]NOP-1A and Cocaine Use Disorders
Completed·UUniversity of Pittsburgh·Phase 1·NCT03348384·49 enrolled
Lorcaserin in the Treatment of Cocaine Use Disorder
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT03007394·272 enrolled
The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders
Completed·YYale University·Phase 1·NCT03953612·58 enrolled
Cocaine Use Disorder and Cortical Dopamine
Completed·UUniversity of Pittsburgh·Phase 1·NCT03349606·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)